These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29644451)

  • 41. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ; Zhang J
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent trends in the management of advanced prostate cancer.
    Ritch C; Cookson M
    F1000Res; 2018; 7():. PubMed ID: 30345007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
    Bracarda S; Logothetis C; Sternberg CN; Oudard S
    BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Therapeutic targeted approaches on androgen receptors in prostate cancer].
    Ferrand FR; Pavic M
    Rev Med Interne; 2014 Oct; 35(10):670-5. PubMed ID: 24934766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer.
    Zhang J; Sun J; Bakht S; Hassan W
    Curr Mol Pharmacol; 2022; 15(1):159-169. PubMed ID: 34102978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of metastatic castration-resistant prostate cancer: recent advances.
    Mukherji D; Eichholz A; De Bono JS
    Drugs; 2012 May; 72(8):1011-28. PubMed ID: 22621691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metastatic Prostate Cancer: Treatment Options.
    Achard V; Putora PM; Omlin A; Zilli T; Fischer S
    Oncology; 2022; 100(1):48-59. PubMed ID: 34781285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent Advances in the Management of Metastatic Prostate Cancer.
    Sayegh N; Swami U; Agarwal N
    JCO Oncol Pract; 2022 Jan; 18(1):45-55. PubMed ID: 34473525
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progress in emerging therapies for advanced prostate cancer.
    Oudard S
    Cancer Treat Rev; 2013 May; 39(3):275-89. PubMed ID: 23107383
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6 Suppl 12):1-15. PubMed ID: 22361744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The evolving options in metastatic castration-sensitive prostate cancer.
    Hamilou Z
    Curr Opin Support Palliat Care; 2020 Sep; 14(3):270-275. PubMed ID: 32701855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
    Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel therapies for metastatic prostate cancer.
    Jang A; Lanka SM; Ruan HT; Kumar HLS; Jia AY; Garcia JA; Mian OY; Barata PC
    Expert Rev Anticancer Ther; 2023; 23(12):1251-1263. PubMed ID: 38030394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
    van Soest RJ; Nieuweboer AJ; de Morrée ES; Chitu D; Bergman AM; Goey SH; Bos MM; van der Meer N; Hamberg P; de Wit R; Mathijssen RH;
    Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Navigating systemic therapy for metastatic castration-naïve prostate cancer.
    Kwan EM; Thangasamy IA; Teh J; Alghazo O; Sathianathen NJ; Lawrentschuk N; Azad AA
    World J Urol; 2021 Feb; 39(2):339-348. PubMed ID: 31897602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
    Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
    J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.